NEJM Volume 394, Issue 9: February 26, 2026 – Medical Research

The ongoing effort to lower prescription drug costs through Medicare negotiation is showing promising early signs, according to research published this week in the New England Journal of Medicine. The study, appearing in the February 26, 2026 issue (Volume 394, Issue 9, pages 835-838), details the initial impact of the Inflation Reduction Act’s provisions allowing Medicare to directly negotiate prices with pharmaceutical companies. This marks a significant shift in how the U.S. Healthcare system addresses drug affordability, a long-standing concern for both patients and policymakers.

Initial Price Reductions and Affected Medications

The analysis focuses on the first ten drugs selected for price negotiation, a list announced in August 2023. These medications treat a range of conditions, including diabetes, heart failure, and blood clots. The study reveals substantial price reductions achieved through the negotiation process, with average savings projected to be around 34% for these specific drugs in 2026. These lower prices are expected to benefit millions of Medicare beneficiaries who rely on these medications. The specific drugs included in the initial negotiation phase are Eliquis (apixaban), Jardiance (empagliflozin), Xarelto (rivaroxaban), Januvia (sitagliptin), Farxiga (dapagliflozin), Entresto (sacubitril/valsartan), Imbruvica (ibrutinib), Stelara (ustekinumab), Fiasp/NovoLog (insulin aspart), and Juvisync/Ozempic (semaglutide). As reported by The Manila Times, the ACTG (AIDS Clinical Trials Group) announced the publication of these results, highlighting the importance of this policy change.

Understanding the Negotiation Process

The Inflation Reduction Act, signed into law in 2022, authorized Medicare to negotiate prices for a limited number of high-expenditure drugs. This negotiation process differs significantly from the traditional system where pharmaceutical companies largely set their own prices. The law prioritizes drugs that have been on the market for a certain period (at least nine years for small-molecule drugs and thirteen years for biologics) and lack generic or biosimilar competition. The negotiated prices are then available to all Medicare beneficiaries, regardless of their specific plan. It’s important to note that this negotiation applies only to drugs covered under Medicare Part D (prescription drug coverage) and Part B (medical insurance, which covers some medications administered by a healthcare professional).

Study Details and Limitations

The New England Journal of Medicine study analyzed data from the Centers for Medicare & Medicaid Services (CMS) regarding the initial price negotiations. Researchers examined the list prices of the selected drugs before and after negotiation, as well as projected savings for Medicare beneficiaries. The study’s strength lies in its use of official CMS data, providing a reliable assessment of the program’s early impact. However, the study also acknowledges several limitations. It focuses solely on the first ten drugs selected for negotiation, and the results may not be generalizable to all drugs subject to future negotiations. The study does not account for potential behavioral responses from pharmaceutical companies, such as altering their pricing strategies for other drugs or reducing investment in research and development. The long-term effects of the negotiation program remain to be seen.

The study also doesn’t delve into the complexities of pharmaceutical innovation. While lowering drug costs is crucial for access, it’s also important to consider the incentives for companies to develop new treatments. Finding the right balance between affordability and innovation is a key challenge for policymakers.

What This Means for Medicare Beneficiaries

For Medicare beneficiaries, the lower drug prices resulting from negotiation translate into significant financial relief. Reduced out-of-pocket costs can make essential medications more affordable, improving adherence and health outcomes. The savings are particularly beneficial for individuals with chronic conditions who require ongoing medication. However, it’s important to remember that these price reductions apply only to the negotiated drugs. Beneficiaries will still face costs for other medications not included in the negotiation program. The full study in the New England Journal of Medicine provides a detailed breakdown of the specific savings for each drug.

The Broader Context of Drug Pricing in the U.S.

The U.S. Has historically had significantly higher drug prices compared to other developed countries. This is due, in part, to the lack of government price controls and the complex system of rebates and discounts negotiated between pharmaceutical companies and pharmacy benefit managers (PBMs). The Inflation Reduction Act’s drug price negotiation provisions represent a major step towards aligning U.S. Drug prices with those in other countries. However, it’s important to note that the program is limited in scope, and further policy changes may be needed to address the broader issue of drug affordability. The Congressional Budget Office (CBO) estimates that the Inflation Reduction Act will reduce federal drug spending by hundreds of billions of dollars over the next decade.

Next Steps and Ongoing Evaluation

The CMS will continue to negotiate prices for additional drugs in the coming years, with more drugs being added to the negotiation list annually. The agency will also monitor the impact of the program on drug innovation and access. Regular evaluations will be conducted to assess the effectiveness of the negotiation process and identify areas for improvement. Ongoing legal challenges from pharmaceutical companies are expected, and the courts will ultimately determine the extent of Medicare’s negotiating power. The Department of Health and Human Services (HHS) is expected to release further guidance on the implementation of the program in the coming months, and beneficiaries should check official updates for the latest information.